Health Condition 1: J449- Chronic obstructive pulmonary disease, unspecified Health Condition 2: I10- Essential (primary) hypertension
Conditions
Interventions
Intervention1: Ramipril 5.0 milligram, Telmisartan 40 milligram: Capsule Ramipril 5.0 mg an angiotensin converting enzyme ii (ACE II) inhibitor and tablet Telmisartan 40 mg, an angiotensin receptor bl
Sponsors
Defense Research and Development Organization Life Science Research Board
Sharda University
Eligibility
Inclusion criteria
Inclusion criteria: A) Control healthy individuals: The healthy individuals will comprise volunteers with no apparent signs and history of any cardio-pulmonary disease. Both male and female volunteers with different age groups and of the same ethnicity will be recruited for the study. They will be recruited in the study after fulfilment of inclusion and exclusion criteria and medical history will be taken with prior written informed consent from all the volunteers. Volunteers with any cardio-pulmonary ailment will be excluded from the study. B) Patients with COPD: Patients reporting to Sharda Hospital with COPD of all three groups (A, B and E according to GOLD guideline 2024) will be recruited for the study after various clinical investigations. Previously diagnosed and newly diagnosed patients treated with standard protocol for COPD for at least 2 months will be recruited. . C) Patients with COPD & Hypertension: Patients of COPD as per criteria mentioned in para B with newly diagnosed or previously diagnosed patients of hypertension, not treated with ACE II inhibitors and ARBs, reporting to Sharda Hospital with any grade of hypertension according to the American College of Cardiology/American Heart Association (ACC/AHA) will be recruited for the study.
Exclusion criteria
Exclusion criteria: Patients with bronchial asthma; active tuberculosis; signs and symptoms of clinically significant neurological, psychiatric, renal, immunological, gastrointestinal and urogenital disorders; endocrine disorders (uncontrolled diabetes or thyroid disease) or uncontrolled haematological disease; unstable liver disease and unstable or life-threatening heart disease; cancer patients and patients with any drug, substance or alcohol abuse etc. will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement or change in Renin Angiotensin Aldosterone and Angiotensin-converting enzyme ii (ACE II)Timepoint: 90 days | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in lung functionTimepoint: 90 days after initiation of treatment;Improvement or changes in inflammatory cytokinesTimepoint: 90 days after initiation of treatment;Changes in high sensitivity C-reactive proteinTimepoint: 90 days after initiation of treatment | — |
Countries
India
Contacts
Public ContactDr Devendra Kumar Singh
Department of Respiratory Medicine, School of Medical Sciences and Research and Sharda Hospital
Outcome results
None listed